文献速递骨质疏松与代谢性骨病

左甲状腺素钠与阿仑膦酸钠新型泡腾制剂联合给药的药代动力学

Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation.
PubMed 文献 · Osteoporos Int · 2017-02-16

在30名健康成人中开展随机、开放标签、三向交叉研究,比较单用阿仑膦酸钠新型泡腾制剂(Aln-NEF)70 mg、单用左甲状腺素(LT4)600 μg及两者联合给药。结果显示联合给药时Aln-NEF与LT4的药代动力学参数几何均值比的90%CI均在80%~125%等效界值内,LT4吸收未受实质性影响,联合给药耐受良好。

要点

  • LT4与Aln-NEF联合给药时,Aln的AUC0-8和Cmax几何均值比分别为0.927和0.912,90%CI均含1。
  • Aln-NEF与LT4联合给药时,LT4的AUC0-48和Cmax几何均值比分别为1.049和1.075,90%CI均含1。
  • 联合给药未出现临床重要的药代动力学干扰,LT4吸收未受实质性影响,耐受良好。

核心结论

  • Aln-NEF与LT4联合给药未出现临床重要的药代动力学干扰,Aln-NEF不实质性影响LT4吸收。

研究设计与样本

  • 随机、开放标签、三向交叉研究,纳入30名健康成人(15名女性)。
  • 受试者间隔35天接受3次给药,分别为单用Aln-NEF 70 mg、单用LT4 600 μg及两者联合给药,均在隔夜空腹后服用。

主要发现

  • Aln-NEF联合LT4与单用Aln-NEF相比,AUC0-8几何均值比为0.927(90%CI 0.795-1.081),Cmax几何均值比为0.912(90%CI 0.773-1.077)。
  • LT4联合Aln-NEF与单用LT4相比,AUC0-48几何均值比为1.049(90%CI 0.983-1.119),Cmax几何均值比为1.075(90%CI 1.006-1.148)。
  • Aln-NEF与LT4联合给药耐受良好。

关键数值与推荐

  • 药代动力学药物相互作用采用几何均值比的90%CI评估,参照默认无效应界值80%~125%。
  • Aln-NEF联合LT4与单用Aln-NEF的AUC0-8和Cmax几何均值比90%CI均落在80%~125%界值内。
  • LT4联合Aln-NEF与单用LT4的AUC0-48和Cmax几何均值比90%CI均落在80%~125%界值内。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: No clinically important pharmacokinetic interference of alendronate occurred between a new effervescent formulation of alendronate and levothyroxine when coadministered. The combination does not materially affect levothyroxine absorption. INTRODUCTION: Concurrent treatment of osteoporosis with alendronate (Aln) and hypothyroidism with levothyroxine (LT4) may be problematic because both drugs are to be taken separately after fasting overnight. The primary objective was to assess pharmacokinetic interactions between a new effervescent formulation of Aln (Aln-NEF) and LT4. METHODS: A randomized, open-label, 3-way crossover study was conducted in 30 healthy adults (15 women). Subjects were dosed 3 times, separated by 35 days, after overnight fasts, with Aln-NEF alone (70 mg), LT4 alone (600 μg), or Aln-NEF and LT4 concurrently. Samples were analyzed for plasma Aln and serum LT4. Pharmacokinetic drug-drug interaction was assessed using 90% confidence intervals (CIs) for the test/reference ratio of the geometric means for area under the concentration-time curve from time zero to last measureable time point (AUC0-t ) and maximum concentration (C max). Results were compared to the default no-effect boundaries of 80 to 125% for the ratio Aln-NEF and LT4 concurrently/Aln-NEF alone and the ratio Aln-NEF and LT4 concurrently/LT4 alone. RESULTS: Geometric mean ratios (Aln-NEF with LT4/Aln-NEF alone) were 0.927 (90% CI 0.795-1.081) for AUC0-8 and 0.912 (90% CI 0.773-1.077) for C max, demonstrating LT4 does not appreciably affect the pharmacokinetics of Aln. Geometric mean ratios (LT4 with Aln-NEF/LT4 alone) were 1.049 (90% CI 0.983-1.119) for AUC0-48 and 1.075 (90% CI 1.006-1.148) for C max, demonstrating LT4 is bioequivalent between the 2 treatments. Coadministration of Aln-NEF and LT4 was well tolerated. CONCLUSIONS: There was no clinically important pharmacokinetic interference between the Aln-NEF formulation and LT4. Aln-NEF does not materially affect LT4 absorption.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Bone HG, Walter MA, Hurley ME, et al. Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation. Osteoporos Int. 2017. PMID: 28204953. doi:10.1007/s00198-017-3941-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。